Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BRAVEHEART who wrote (393)	12/1/1998 2:11:00 PM
From: Dr. John M. de Castro	Read Replies (1) of 1494

Merz awarded prize for memantine development. I found this on the Merz site. The prize was awarded in June, but this is the first I've heard about it. This is an indicator of just how promising Memantine is for the treatment of Dementia. NTII will receive a piece of the profits from this market. "Merz + Co. was awarded the prize "Fortschritte der Geriatrie 1998" for the development of the NMDA Antagonist Memantine. On the occasion of the 9th medical education congress "Geriatrie Praxis" in Neuss, this year's award "Fortschritte der Geriatrie" was presented to honor the NMDA antagonist Memantine which was developed by the Frankfurt-based Merz + Co. This award has been presented since 1990 by the journal "Geriatrie Praxis" for outstanding geriatric research. In this context, the intensive commitment of Merz + Co. in geriatrics through providing patient information and medical training was honored." John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next